Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Berger

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Clinical Pharmacokinetics|July 1, 2015
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover StudyAdrian Derungs, Massimiliano Donzelli, Benjamin Berger, et al.
Journal of the Neurological Sciences|September 23, 2016
Prevalence of anti-SOX1 reactivity in various neurological disordersBenjamin Berger, Rick Dersch, Elisabeth Ruthardt, et al.
CNS Drugs|November 18, 2020
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy SubjectsBenjamin Berger, Sander Brooks, Rob Zuiker, et al.
Pharmacology Research & Perspectives|October 6, 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjectsBenjamin Berger, Priska Kaufmann, Matthias Berse, et al.
Neurocritical Care|January 17, 2012
Accidental intoxication with 60 mg intrathecal baclofen: survivedBenjamin Berger, Barbara Vienenkoetter, Mirjam Korporal, et al.
Journal of Neuroimmunology|April 24, 2015
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessationBenjamin Berger, Annette Baumgartner, Sebastian Rauer, et al.
Clinical Pharmacokinetics|May 18, 2021
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor AntagonistBenjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
British Journal of Pharmacology|June 6, 2006
Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortexBenjamin Berger, Anna Katharina Rothmaier, Franziska Wedekind, et al.
Fluids and Barriers of the CNS|December 15, 2015
The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohortTilman Hottenrott, Rick Dersch, Benjamin Berger, et al.
Frontiers in Immunology|June 16, 2023
Therapy response in seronegative versus seropositive autoimmune encephalitisBenjamin Berger, Sophie Hauck, Kimon Runge, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Clinical Pharmacokinetics|July 1, 2015
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover StudyAdrian Derungs, Massimiliano Donzelli, Benjamin Berger, et al.
Journal of the Neurological Sciences|September 23, 2016
Prevalence of anti-SOX1 reactivity in various neurological disordersBenjamin Berger, Rick Dersch, Elisabeth Ruthardt, et al.
CNS Drugs|November 18, 2020
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy SubjectsBenjamin Berger, Sander Brooks, Rob Zuiker, et al.
Pharmacology Research & Perspectives|October 6, 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjectsBenjamin Berger, Priska Kaufmann, Matthias Berse, et al.
Neurocritical Care|January 17, 2012
Accidental intoxication with 60 mg intrathecal baclofen: survivedBenjamin Berger, Barbara Vienenkoetter, Mirjam Korporal, et al.
Journal of Neuroimmunology|April 24, 2015
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessationBenjamin Berger, Annette Baumgartner, Sebastian Rauer, et al.
Clinical Pharmacokinetics|May 18, 2021
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor AntagonistBenjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
British Journal of Pharmacology|June 6, 2006
Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortexBenjamin Berger, Anna Katharina Rothmaier, Franziska Wedekind, et al.
Fluids and Barriers of the CNS|December 15, 2015
The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohortTilman Hottenrott, Rick Dersch, Benjamin Berger, et al.
Frontiers in Immunology|June 16, 2023
Therapy response in seronegative versus seropositive autoimmune encephalitisBenjamin Berger, Sophie Hauck, Kimon Runge, et al.
Pageof 7